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sents a delicate balance between the degradation
and the synthesis of extra-cellular matrix compo-
nents to maintain the functional integrity of the
joint. Under the influence of mechanical stress or
joint inflammation, this dynamic equilibrium is
broken and catabolic events progressively become
prevalent leading to cartilage destruction.
Animal models in the study of the development
of osteoarthritis have identified two types of repair
reactions that correspond to the depth of the
injury. The reparative process of osteochondral
defects involves the release of mesenchymal cells
from subchondral bone. The extent of the repair
is influenced by the width, direction and site
of the injury. Better repair is observed when the
injury is parallel to the direction of joint motion
[1]. However, the histologic, biochemical and bio-
mechanical characteristics of the repair tissue are
di#erent from normal cartilage. The repair of
chondral defects occur early following the induced
cartilage lesion. The repair tissue is characterized
by chondrocyte clustering (mitosis and/or migra-
tion), cartilage hypertrophy, an increase in glycos-
aminoglycan (GAG), fibronectin, and water carti-
lage content, and an enhancement of GAG and
collagen (types II and III but not type I) synthesis
by chondrocytes [2].
Unfortunately, the repair tissue ultimately fails
and cartilage destruction ensues. Chondrocytes
progressively decompensate, start secreting more
proteolytic enzymes and catabolic cytokines and
finally die probably by apoptosis (Fig. 1).
Questions remain concerning the repair process.
It is unknown at what point the repair process
ends and cartilage damage becomes irreversible.
Many of the circumstances leading to aborted
repair reaction remain unknown. Several factors
could be involved, including alteration in the car-
tilage macromolecule structure, chondrocyte phe-
notypic change, IL-1 overproduction, increase
susceptibility of chondrocytes to cytokine-induced
degradation, focal over-expression of IL-1 and31tumor necrosis factor (TNF) Æ receptors, growth
factor synthesis and bioactivity down-regulation,
reduction of chondrocyte sensitivity to growth
factors, chondrocytes apoptosis, etc. [3–6].
The cartilage repair reaction is regulated by
soluble factors produced locally by chondrocytes
and neighboring tissues, mainly synovial mem-
brane and bone. The most important factors
involved in the control of the repair reaction are
tranforming growth factor (TGF)-â, basic fibro-
blast derived growth factor (bFGF), insulin like
growth factor (IGF)-1, interleukin (IL)-1 (Æ and â)
and TNFÆ. Nevertheless, factors including platelet
derived growth factor (PDGF), bone morphogenic
proteins (BMPs) or cartilage-derived morphoge-
netic proteins (CDMPs) could also have an import-
ant regulatory function. TGFâ and IGF-1 play a
significant role in promoting chondrocyte anabo-
lism and inhibiting chondrocyte catabolism
whereas IL-1â and TNFÆ inhibit cartilage matrix
component synthesis and promote cartilage
destruction by increasing metalloproteinase syn-
thesis by chondrocytes. TGF-â and IGF-1 may
partially reverse IL-1â-mediated degradation of
articular cartilage [7, 8].
The imbalance between anabolic growth factors
and catabolic cytokine synthesis and/or bioactiv-
ity could be the key of cartilage repair failure.
Several mechanisms can control growth factors
and cytokine bioactivity during the development
of osteoarthritis. Interactions with binding pro-
teins, soluble receptors, matrix components (e.g.,
decorin), or with other growth factors or cytokines
may modulate their e#ects on chondrocyte
metabolism.
On the basis of these experimental considera-
tions, therapeutic intervention to promote the car-
tilage reparative process in osteoarthritis becomes
more evident. Intraarticular injection of growth
factors, interleukin-1 receptor antagonist (IL-1ra),
docyxycline or nitric oxide (NO) synthase inhibi-
tors has been tested successfully on experimental
models of osteoarthritis [9, 10]. These substances0
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FIG. 1. The reparative attempt of chondral defect in which injury is limited to cartilage.can prevent the development of osteoarthritis or
reduce the severity of the lesions. Gene therapy
o#ers an elegant therapeutic alternative. Transfer
of an appropriate gene(s) into chondrocytes or
synoviocytes prior to transplantation, may allow a
high level of expression of growth factors in vivo
for an extended period of time [11, 12].
However, prolonged high expression of growth
factor transgene could lead to focal cartilage
hyperplasia with loss of articular surface congru-
ity, promoting osteophyte formation. Drugs which
inhibit metalloproteanase activity/synthesis or
IL-1 synthesis could also prolong the reparative
response. Finally, if administrated during the early
period of osteoarthritis, drugs stimulating carti-
lage matrix synthesis by chondrocytes could also
be valuable tools to sustain repair reaction.
In conclusion, it is important to consider that
the chondrocyte metabolic activity at the early
stage of the osteoarthritis is di#erent from that
associated with the progression of the disease.
Therefore, the possibility must be considered that
therapeutic agents or growth factors, which are
e#ective in the initial stage , may lose their e#ec-
tiveness at the later stages of the disease and vice
versa. This possibility must be taken in account in
the design of experimental protocol studying the
e#ect of potential structure or disease modifying
osteoarthritis drugs (DMOAD).
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